JS001

DRUG12 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Sun Yat-sen University, Xu jianmin, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Elpiscience Biopharma, Ltd.

Conditions

Advanced Esophageal Squamous Cell CarcinomaColorectal CancerEfficacy and SafetyEsophageal Small Cell CarcinomaGastric CancerHead and Neck Squamous Cell CarcinomaLocally Advanced Solid TumorLung Cancer

Phase 1

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.Lung Cancer, Lymphoma

Start: 2016-08-31End: 2020-12-31Updated: 2019-10-22

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Sun Yat-sen UniversityColorectal Cancer

Start: 2019-03-12End: 2021-11-20Updated: 2020-05-12

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

CompletedNCT04991506

Elpiscience Biopharma, Ltd.Malignant Tumor, Neoplasms, Solid Tumor

Start: 2021-10-15End: 2024-05-17Updated: 2025-06-23

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not yet recruitingNCT06370754

Fudan UniversityPancreatic Cancer

Start: 2024-04-30End: 2027-04-30Target: 117Updated: 2024-04-17

Phase 2

Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.

WithdrawnNCT03623776

Sun Yat-sen UniversityEfficacy and Safety

Start: 2019-02-01End: 2026-12-01Updated: 2024-12-06

A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer

Xu jianminColorectal Cancer

Start: 2019-07-17End: 2021-07-17Target: 40Updated: 2019-10-08

Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer

Sun Yat-sen UniversityGastric Cancer, Locally Advanced Solid Tumor

Start: 2019-10-12End: 2024-10-05Updated: 2023-08-01

Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityHead and Neck Squamous Cell Carcinoma

Start: 2020-08-10End: 2024-08-09Target: 316Updated: 2021-04-15

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

RecruitingNCT05173246

Sun Yat-sen UniversityEsophageal Small Cell Carcinoma

Start: 2020-11-17End: 2026-12-31Target: 43Updated: 2025-07-16

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

RecruitingNCT05297552

RemeGen Co., Ltd.Muscle Invasive Bladder Carcinoma

Start: 2022-05-26End: 2025-02-28Target: 40Updated: 2024-02-20

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Not yet recruitingNCT07484724

Shanghai Junshi Bioscience Co., Ltd.Advanced Esophageal Squamous Cell Carcinoma

Start: 2026-04-01End: 2028-04-01Target: 280Updated: 2026-03-23

Phase 3

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruitingNCT04085276

Shanghai Junshi Bioscience Co., Ltd.Triple-Negative Breast Cancer

Start: 2018-12-21End: 2025-12-31Updated: 2025-06-11

Related Papers

Perioperative PD-1 antibody toripalimab combined with chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction cancer: 3-year follow-up of the prospective, randomized, phase 2 NEOSUMMIT-01 trial.

Journal of Clinical Oncology2026-01-10

Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.

Journal of Clinical Oncology2025-02-1013 citations

Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.

Journal of Clinical Oncology2024-06-0110 citations

Survival outcomes of concurrent radiotherapy and toripalimab versus radiotherapy alone for elderly patients with postoperative head and neck squamous cell carcinoma unfit for cisplatin.

Journal of Clinical Oncology2024-06-011 citations

Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer

Frontiers in Oncology2024-01-181 citations

Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.

2024-01-0273 citations

Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT)

Frontiers in Oncology2023-10-054 citations

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).

Journal of Clinical Oncology2023-06-075 citations

Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.

Journal of Clinical Oncology2023-06-0119 citations

Feasibility and quality of life of postoperative concurrent radiotherapy and toripalimab in elderly patients with head and neck squamous cell carcinoma (IMPORT trial).

Journal of Clinical Oncology2022-06-01

Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.

2021-10-2420 citations

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.

2020-03-2750 citations

Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.

Journal of Clinical Oncology2018-05-205 citations

Phase 1 trial of JS001, a monoclonal antibody targeting programed death-1 (PD-1) in patients with advanced or recurrent malignancies.

Journal of Clinical Oncology2018-05-201 citations

A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.

Journal of Clinical Oncology2017-05-202 citations